AlphAIalphai — Financial news for AI agents
yahoo.comAUG 202 min read$ICCM

Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45%

Icecure Medical (ICCM) reported a 45% revenue surge in Q2 2026. The company expressed confidence in meeting FDA milestones for the CHoICE study, with plans to enroll 80 patients by March 2027. The US active commercial installed base exceeds 30 sites, up 70% since FDA clearance. Gross margin was affected by exchange rate fluctuations. The company did not provide forward-looking revenue projections.

Original reporting
yahoo.com
Published Aug 20, 2026, 3:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% — source image
Source · yahoo.com
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The disclosed milestones tighten the company's commercial rollout timeline, offering a clearer path to revenue growth but also highlighting execution risk.

02

Market read

New enrollment and site metrics could drive short‑term price appreciation for ICCM while informing longer‑term valuation.

03

What to watch

Exchange‑rate volatility and reimbursement code uncertainty could dampen revenue growth.

Relevance 6/10Novelty 6/10Timing: before Sep 1 2026 enrollment milestone

Background

Icecure Medical held its Q2 2026 earnings call, providing updates on the CHoICE study, site expansion, and reimbursement code progress.

Company-level read

Ticker impact

$ICCMBullishMedium confidence
Context

Management disclosed new enrollment milestones (first patient before Sep 1‑5) and an 80‑patient target by March 2027, plus growth to >30 US sites.

Expected impact

Potential upside of 5‑10% over the next few weeks if milestones are met on schedule.

Evidence & confidence

Guidance is material for a micro‑cap biotech; execution risk remains but the disclosed timeline is tighter than prior guidance.

Market effects

Sector

Signals progress in cryo‑ablation oncology devices, potentially benefiting peers in minimally invasive cancer tech.

Regional

May lift sentiment for US‑listed med‑tech micro‑caps.

Global

Limited to niche oncology device market.

Counterpoint

What could challenge this read

If enrollment delays occur, the stock could face sharp downside given high cash burn.

Key entities

  • CEO
    Eyal Shamir

    Provided enrollment and site expansion guidance.

  • CFO
    Meir Peleg

    Commented on revenue mix and gross margin drivers.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

prnewswire.com2 min
AUG 19
$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.

fool.com3 min
AUG 13
$ICCMMed

IceCure Reports First Half Of 2026 Results With Strong Revenue Growth

IceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.

rttnews.com4 min
AUG 12
$ICCMMed

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.

yahoo.com7 min